Boston Scientific surges 10% in Q1 amid slew of FDA nods, company reorganization

Boston Scientific may have slimmed down its sprawling corporate structure in the first quarter of the year, but that didn’t keep it from plumping up its earnings for the period.

The medtech's net sales jumped 10% over its performance during the same period last year. The total reached just past the $3 billion threshold, compared to the $2.75 billion it earned in the first three months of 2021.